The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model by unknown
ORIGINAL PAPER
The multistate tuberculosis pharmacometric model: a semi-
mechanistic pharmacokinetic-pharmacodynamic model
for studying drug effects in an acute tuberculosis mouse model
Chunli Chen1 • Fatima Ortega2 • Joaquin Rullas2 • Laura Alameda2 •
In˜igo Angulo-Barturen2,3 • Santiago Ferrer2 • Ulrika SH Simonsson1
Received: 8 September 2016 / Accepted: 30 January 2017 / Published online: 15 February 2017
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract The Multistate Tuberculosis Pharmacometric
(MTP) model, a pharmacokinetic-pharmacodynamic dis-
ease model, has been used to describe the effects of
rifampicin on Mycobacterium tuberculosis (M. tuberculo-
sis) in vitro. The aim of this work was to investigate if the
MTP model could be used to describe the rifampicin
treatment response in an acute tuberculosis mouse model.
Sixty C57BL/6 mice were intratracheally infected with M.
tuberculosis H37Rv strain on Day 0. Fifteen mice received
no treatment and were sacrificed on Days 1, 9 and 18 (5
each day). Twenty-five mice received oral rifampicin (1, 3,
9, 26 or 98 mgkg-1day-1; Days 1–8; 5 each dose level)
and were sacrificed on Day 9. Twenty mice received oral
rifampicin (30 mgkg-1day-1; up to 8 days) and were
sacrificed on Days 2, 3, 4 and 9 (5 each day). The MTP
model was linked to a rifampicin population pharmacoki-
netic model to describe the change in colony forming units
(CFU) in the lungs over time. The transfer rates between
the different bacterial states were fixed to estimates from
in vitro data. The MTP model described well the change in
CFU over time after different exposure levels of rifampicin
in an acute tuberculosis mouse model. Rifampicin signifi-
cantly inhibited the growth of fast-multiplying bacteria and
stimulated the death of fast- and slow-multiplying bacteria.
The data did not support an effect of rifampicin on non-
multiplying bacteria possibly due to the short duration of
the study. The pharmacometric modelling framework using
the MTP model can be used to perform investigations and
predictions of the efficacy of anti-tubercular drugs against
different bacterial states.
Keywords Mouse  Rifampicin  Tuberculosis 
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Introduction
Tuberculosis is an infectious disease caused by Mycobac-
terium tuberculosis (M. tuberculosis). Without treatment,
mortality rates are high. Rifampicin is an antibiotic dis-
covered in the year of 1957 in the Dow-Lepetit Research
Laboratories and used to treat drug-susceptible tuberculosis
along with isoniazid, pyrazinamide and ethambutol. The
mouse is commonly used as a pre-clinical experimental
animal model for evaluating the in vivo efficacy of anti-
tubercular compounds, mainly for practical reasons
including its size, low associated costs and highly repro-
ducible experimental infections and therapeutic outcomes.
The colony forming unit (CFU), a quantification of the
bacterial burden in different tissues or fluids [1, 2], is a
commonly used pharmacodynamic (PD) endpoint. Bacte-
rial burden is often described using summary PD endpoints
such as extent of bacterial killing (e.g. change in CFU at
the end of treatment or representative measurements from
the bacterial time-kill curves) or rate and duration of
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bacterial killing (e.g. maximal kill rate or time to reach a
certain level of bacteria). These summary PD endpoints do
not completely characterise the pharmacokinetics (PK), PD
and efficacy over time. The PK/PD indices approach is also
commonly used for evaluating the PK and PD of antibiotics
and for guiding dose selection [3, 4]. However, the PK/PD
indices have several drawbacks as they ignore the time-
courses of the PK, PD and bacterial dynamics [5].
The Multistate Tuberculosis Pharmacometric (MTP)
model [6] is a semi-mechanistic PK–PD model for studying
anti-tubercular drug effects which was developed using
in vitro data. It has further been extended to use for clinical
data and proven to be able to be used for clinical trial
simulations [7]. The model predicts the changes in the
numbers of bacteria in the different states (fast-, slow- and
non-multiplying bacterial states) with and without drug
effects as well as CFU over time. It thus provides a basis
for investigating and predicting the effects of anti-tuber-
cular drugs and novel compounds on these bacterial states
and CFU. Disease models define the underlying system of
the disease and can incorporate the relationships between
biomarkers and clinical outcomes, the time course of the
disease and potential placebo effects. The parameters of
disease models are system-specific, in contrast to those of
empirical models where the parameters are both system-
specific and drug-specific. A disease model is often linked
to a drug model which describes the PK of the drug. Given
the disease model and the PK model, the relationship
between exposure and response (PK–PD) can be defined.
Disease models are available for several therapeutic areas
for example malaria [8], myelosuppression [9] and glu-
cose-insulin regulation [10]. The myelosuppression disease
model has been shown to be applicable across drugs and
various phases of drug development [9, 11]. A similar
strategy for tuberculosis drug development using the MTP
model would allow the effect on the time-course of CFU
due to drug(s) to be predicted in patients from in vivo
(animal) and in vitro information.
The aim of this work was to relate rifampicin exposure
to the changes in CFU over time in an acute tuberculosis
mouse model using the MTP modelling approach.
Methods
Chemicals
All chemicals and reagents were obtained from
GlaxoSmithKline (GSK). Water was purified and de-
ionised using the water purified system. The drugs were
orally administered in a solution of EncapsinTM 20% and
water 80%.
Rifampicin pharmacodynamic mouse study
Sixty C57BL/6 mice were anaesthetised with 3% isoflurane
(IsoVet, B.Braun, Piramal Healthcare, Maharashtra,
India) and intubated with a metal probe (catalogue number
27134, Unimed SA, Lausanne, Switzerland). Infection was
initiated by intratracheal instillation of M. tuberculosis
H37Rv. The inoculum (105 CFU per mouse suspended in
50 ll of phosphate-buffered saline) was put into the probe
and delivered through forced inhalation with a syringe on
Day 0. Twenty-five mice received rifampicin (Sigma-
Aldrich) 1.00, 2.83, 8.88, 26.4 or 98.0 mgkg-1day-1
orally once daily for 8 days from Day 1 (24 h after
infection) and samples were taken after sacrifice on Day 9
after infection. An additional 20 mice were given
30 mgkg-1 rifampicin orally once daily for up to 8 days.
Five of these were sacrificed on each of Days 2, 3, 4 and 9
after infection. Fifteen mice received no treatment (natural
growth group) and were sacrificed on Days 1, 9 and 18
(five mice on each occasion).
In order to quantify the infection burden in the lungs, all
lung lobes were aseptically removed and homogenised.
After addition of glycerol (5%), the homogenates were
stored frozen (-80 C) until plating in 10% OADC-7H11
medium for 14 days at 37 C. After culture, the colonies
were counted using an automatic colony counter (a
COLyte-Supercount, Synoptics Ltd., Cambridge, United
Kingdom), confirmed by visual inspection. The study was
ethically reviewed and carried out in accordance with
European Directive 2010/63/EU and the GSK Policy on the
Care, Welfare and Treatment of Animals.
The multistate tuberculosis pharmacometric model
A rifampicin population PK model including auto-induc-
tion earlier developed in the mouse [12] was linked to the
MTP model [6], using a population pharmacokinetic
parameter (PPP) approach [13], since PK data was not
obtained in this study. This allowed predicting typical
rifampicin blood concentrations over time, based on the
rifampicin drug regimens applied in this study, as the input
to the MTP model. In brief, the population PK model
consisted of a one compartment with first-order absorption
and elimination (Fig. 1). The volume of distribution at the
lowest dose (1.02 mgkg-1) of rifampicin was 2280 and
1250 mLkg-1 for the higher doses. Due to auto-induction
of rifampicin, clearance on Days 1 and 2 (79.3 mLh-1kg-1)
was statistically significantly lower than that on other days,
which was estimated to be 132 mLh-1kg-1. The
bioavailability was estimated as 65.6%. The MTP model
was simultaneously fitted to all observed CFU (log trans-
formation both sides) versus time data. The MTP model
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consists of a series of differential equations representing
fast-multiplying (F), slow-multiplying (S) and non-multi-
plying (N) bacterial states (Fig. 1), with first-order linear
rate to represent the transfers between states. The estimates
of the transfer rates were taken from fitting the MTP model
to in vitro data with the same bacterial strain [6], except for
the time-dependent transfer rate from fast (F)- to slow (S)-
multiplying bacteria (kFS), which was re-estimated using
EMAX and linear functions with respect to time in this study
(Eqs. 1–2). Re-estimation of kFS as well as other transfer
rates, one at a time, was compared to fixing the parameter
to the in vitro estimates [6].
kFS ¼ KFSlin  t ð1Þ
kFS ¼ KFSsig 
tMAX  t
t50 þ t ð2Þ
where t is time; KFSlin is the linear increase in kFS with time;
KFSsig is the initial transfer rate from F to S; tMAX is the time
to reach the highest value of kFS; and t50 is 50% of tMAX. The
growth in CFU in un-treated animals was explored using
exponential and Gompertz growth functions. All parameters
associated with the natural growth (kG, kFS, kSF, kFN, kSN,
kNS) were fixed during the estimation of drug effect. The
anti-tubercular effects of rifampicin were evaluated for each
possible mechanism in the model, i.e. inhibition of the
growth of fast-multiplying bacteria and stimulation of the
death of fast-, slow- and non-multiplying bacteria. Different
exposure–response relationships were evaluated for each
possible mechanism such as linear model, EMAX model, and
sigmoidal EMAX model. An exposure–response relationship
for each possible effect site was first evaluated alone.
Thereafter, all statistical exposure–response relationships
were combined and evaluated for statistical significance
jointly compared to alone. A final backward evaluation step
was also carried out, where the exposure–response rela-
tionships were reduced to their simpler forms. A statistically
significant criterion of a decrease in the objective function
value (OFV) of 3.84, corresponding to a 5% significance
level at one degree of freedom was used.
The lower limit of quantification (LLOQ) was 10 CFU/
lungs. The M3 method in NONMEM was used to account
for PD data below the LLOQ (21.6%). The M3 method, as
suggested by Beal et al. [14], is based on simultaneous
modelling of continuous and categorical data where the
Fig. 1 Schematic illustration of the Multistate Tuberculosis Pharma-
cometric model consisting of fast- (F), slow- (S) and non-multiplying
(N) bacterial compartments. The bacterial system was described using
the growth rate (kG) of the fast-multiplying bacteria, a time-dependent
linear rate parameter kFSlin , the transfer rate from fast- to slow-
multiplying bacterial states (kFS), the first-order transfer rate from
slow- to fast-multiplying bacterial states (kSF), the first-order transfer
rate from fast- to non-multiplying bacterial states (kFN), the first-order
transfer rate from slow- to non-multiplying bacterial states (kSN) and
the first-order transfer rate from non- to slow-multiplying bacterial
states (kNS). The rifampicin population pharmacokinetic model was a
one-compartment model with first-order absorption and elimination
accounting for auto-induction. The rifampicin blood concentration
(CRIF) was assumed to inhibit the growth of fast-multiplying bacteria
and stimulate the death of fast- and slow-multiplying bacteria.
FGIMAX = the maximum achievable fractional rifampicin-induced
inhibition of fast-multiplying bacterial growth rate; FDEMAX = the
maximum achievable fractional rifampicin-induced stimulation of
fast-multiplying bacterial death rate; FGIC50 and FDEC50 = the
rifampicin concentrations at 50% of FGIMAX and FDEMAX ; c = sig-
moidicity parameter; SDk = the second-order slow-multiplying bac-
terial death rate; ka = absorption rate constant; CL
* = clearance,
different between Days 1–2 compared to Days 3–8; V = volume of
distribution, different at the lowest dose
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observations below the LLOQ are treated as categorical
data. All observations above the LLOQ were estimated
using the maximum likelihood estimation method. The
likelihoods for observation below the LLOQ were taken to
be the likelihood that these observations are indeed LLOQ.
Additive and combined error models were evaluated to
describe the residual unexplained variability.
Model selection and evaluation
All modelling was carried out using NONMEM software
and FOCE with interaction and Laplace (version 7.3; Icon
Development Solutions, Ellicott City, MD, USA) [15].
Model selection was based on the OFV, where a decrease
of 3.84 was considered significant (p\ 0.05) for one
degree of freedom. In addition, scientific plausibility,
parameter precision and predictive performance (assessed
using a visual predictive check) were used for model
selection. In the visual predictive check, 1000 replicates
were simulated for the model and 5th, median and 95th
percentiles were used with the corresponding data to assess
the model performance in Perl-speaks-NONMEM (PsN)
(version 4.2.0; Department of Pharmaceutical Biosciences,
Uppsala University, Sweden) [16]. Xpose (version 4.4.1;
Department of Pharmaceutical Biosciences, Uppsala
University, Sweden) [16] was used to visualise the data and
results. The run record was produced with Pirana software
(version 2.7) [17].
Results
Simulated typical rifampicin blood concentrations versus
time after the different doses at Day 8 after infection are
shown in Fig. S1. The final structure of the PK model
linked to the MTP model describing the change in CFU
over time is shown in Fig. 1. The MTP model bacterial
transfer rate constants, except kFS, were fixed in this work
to estimates obtained for the same bacterial strain in vitro
[6]. Re-estimating the transfer rate from F to S (kFS) as a
linear function with time provided a decrease in OFV of
7.3 points, compared to fixing the parameter to the in vitro
estimate [6]. Re-estimation of the other transfer rates
between the states did not provide a reduction in OFV and
was therefore fixed to in vitro estimates [6]. The final
model included an exponential growth function for M.
tuberculosis with an exponential growth rate kG. The initial
number (inoculum) of fast-multiplying bacteria in
untreated mice (F0
) differed compared to those in the
rifampicin-treated groups (F0). The data did not support
inclusion of any inoculum of slow- or non-growing bacteria
and these were therefore set to zero in the final model.
The final MTP model included statistically significant
and separate rifampicin effects on inhibition of the growth
of fast-multiplying bacteria (IFG; Eq. 3), stimulation of the
death of fast-multiplying bacteria (EFD; Eq. 4) and stimu-
lation of the death of slow-multiplying bacteria (ESD;
Eq. 5). An effect of rifampicin on the non-multiplying
bacteria was tested but was not statistically significant and
therefore not included in the final model.
IFG ¼ FGIMAX  CRIF
FGIC50 þ CRIF
ð3Þ








ESD ¼ SDk  CRIF ð5Þ
where FGIMAX is the maximal achievable fractional rifam-
picin-induced inhibition of fast-multiplying bacterial
growth rate; FDEMAX is the maximal achievable frac-
tional rifampicin-induced stimulation of fast-multiplying
bacterial death rate; FGIC50 and FDEC50 are the rifampicin
concentrations at 50% of FGIMAX and FDEMAX , respectively;
SDk is the second-order slow-multiplying bacterial death
rate; c is a sigmoidicity parameter; and CRIF is the rifam-
picin blood concentration. The final differential equation
systems for fast-multiplying bacteria (F; Eq. 6), slow-
multiplying bacteria (S; Eq. 7), and non-multiplying bac-
teria (N; Eq. 8) changing over time were as follows:
dF
dt
¼ kG  1 IFGð Þ  F  EFD  F  kFS  F þ kSF  S




¼ kFS  F  kSF  S þ kNS  N  kSN  S ESD  S ð7Þ
dN
dt
¼ kFN  F þ kSN  S kNS  N ð8Þ
where F, S and N represent fast-, slow- and non-multi-
plying bacteria, respectively. The transfer rates between the
bacterial states are given by kFS, kSF, kFN, kSN and kNS, as
shown in Fig. 1.
An additive residual error was used to describe the
residual variability using log transformation on both sides.
Final parameter estimations for theMTPmodel are shown in
Table 1. The visual predictive check based on the final
model for the rifampicin-treated 30 mgkg-1day-1 group
and with longitudinal CFU data is shown in Fig. 2. The final
model predicted the data well for untreated (natural growth)
mice, captured the bi-exponential decline in CFU following
rifampicin 30mgkg-1 over time after infection (Fig. 2) and
also described nicely the CFU change after different doses at
Day 9 after infection (Fig. 3). The predicted bacterial
numbers in the different bacterial states over time without
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rifampicin treatment (natural growth) and after different
rifampicin doses are shown in Fig. 4. The final NONMEM
code is available in the supplement S2.
Discussion
In this study, we describe the application of the MTP
model to the CFU data from an acute tuberculosis mouse
model. We have shown that the MTP model, which was
originally developed using in vitro data [6], can be applied
to mouse data by re-estimating the growth function, initial
bacterial amounts (F0) and the transfer rate for bacterial
transfer from fast- to slow-multiplying bacterial states
(kFS). All other parameters in the MTP model, including
transfer rates kSF, kNS, kSN and kFN were fixed to estimates
from applying the MTP model to in vitro data [6]. Linkage
of a previously developed rifampicin population PK model
[12] to the MTP model allowed the estimation of expo-
sure–response relationships for rifampicin for the different
bacterial states in the final model. The final model descri-
bed the observed CFU versus time profiles well for both
natural growth data and data from rifampicin-treated ani-
mals (Fig. 2 and Fig. 3). The final model predicted the
number of bacteria in the different states over time without
rifampicin treatment (natural growth) and after different
rifampicin dose levels (Fig. 4). The oscillation in the pre-
dicted numbers of fast- and slow-multiplying bacteria was
directly related to the PK of rifampicin. Because the data
did not support an effect of rifampicin on non-multiplying
bacteria, the numbers of non-multiplying bacteria did not
oscillate and the increase in non-multiplying bacteria over
time was the result of transfer from other bacterial states
and the indirect effects of bacterial growth. The growth rate
(kG) of fast-multiplying bacteria was best described by an
exponential function, because of the lack of plateau CFU
data in this mouse model and the short duration of the
study. A simplified bacterial growth function like this has
been used in the other study [18]. The transfer rate from
fast- to slow-multiplying bacteria (kFS) was linearly time
dependent within the time range of this study wherefore
predictions outside the observed time range cannot be
made. The MTP model does not include a natural death
rate, based on evidence from an in vitro study [19] showing
that the majority of bacilli entered into a viable but non-
culturable stage on solid media which was recoverable in
the presence of a resuscitation-promoting factor (Rpf). The
presence of a large number of Rpf-dependent bacteria was
also found in vivo study [19]. These results indicate that
the bacilli did not die naturally within the experimental
duration of our study, but instead entered into a non-mul-
tiplying bacterial state represented by the N-state in the
MTP model, which can only be resuscitated by Rpf. We
fixed the transfer rate between each bacterial state
according to an earlier in vitro study [6], except kFS, which
was re-estimated as a linear function of time. This provided
Table 1 Final parameter estimates of the Multistate Tuberculosis Pharmacometric (MTP) model for rifampicin in an acute tuberculosis mouse
model
Parameter Description Typical Value RSE (%)
F0 (lungs
-1) Initial number of bacteria in a fast-multiplying bacterial state in treated mice 331000 54.1
F0
 (lungs-1) Initial number of bacteria in a fast-multiplying bacterial state in untreated mice 8340 8.7
kG (h
-1) Growth rate of the fast-multiplying bacteria 0.0333 4.4
kFSlin (h
-2) Time-dependent transfer rate from fast- to slow-multiplying bacterial states 2.9610-5 29.8
kSF (h
-1) First-order transfer rate from slow- to fast-multiplying bacterial states 6.0410-4 FIX*
kFN (h
-1) First-order transfer rate from fast- to non-multiplying bacterial states 3.7410-8 FIX*
kSN (h
-1) First-order transfer rate from slow- to non-multiplying bacterial states 7.7510-3 FIX*
kNS (h
-1) First-order transfer rate from non- to slow-multiplying bacterial states 5.1210-5 FIX*
FGIMAX Maximum achievable fractional rifampicin-induced inhibition of fast-multiplying
bacterial growth rate
0.716 16.2
FGIC50 (lgmL-1) Rifampicin concentration at 50% of FGIMAX 0.0397 50.2
c Sigmoidicity parameter 2.19 7.2
FDEMAX (h
-1) Maximum achievable fractional rifampicin-induced stimulation of fast-
multiplying bacterial death rate
352 12.8
FDEC50 (lgmL-1) Rifampicin concentration at 50% of FDEMAX 212 30.4
SDk (mLh-1lg-1) Second-order slow-multiplying bacterial death rate 4.9110-3 12.9
Error Additive residual error variability (variance) on log scale 0.217 12.0
FIX*: Fixed to estimates from application of the MTP model in vitro [6]
F fast-multiplying bacteria; S slow-multiplying bacteria; N non-multiplying bacteria; RSE relative standard error reported on the approximate
standard deviation scale
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a significant drop in OFV (7.3 points), whereas re-esti-
mation of the other rate constants was not statistically
significant. The CFU data in this study did not contain
enough information about transfer rate from the other
bacterial states which was evident in the in vitro data [6].
The final model included rifampicin statistically different
drug effects on both an inhibition of the growth and a
stimulation of the death of fast-multiplying bacteria which
was possible likely due to the cap of the inhibition of the
growth through the parameter FGIMAX as well as the very
distinct different exposure–response relationships. The
EC50s for the two processes were very different (0.04 vs.
212, Table 1). The two exposure–response relationships
affecting fast-mutiplying bacterial state i.e. inhibition of
the growth and stimulation of the death, were both statis-
tically significant. Removing the drug effect on the inhi-
bition of the growth or stimulation of the death of fast-
multiplying bacteria led to an increase in OFV by 9 and
211 points, respectively, indicating that two separate pro-
cesses of drug effect were described. Omitting the drug
effect on the stimulation of the death of slow-multiplying
bacteria led to an increase in OFV by 15 points i.e. the drug
effect on the slow-multiplying bacterial state was also
statistically significant. The CFU count is a sum of the total
number of bacteria that are able to multiply on solid media
and as such, the CFU assay is not possible to directly
distinguish between fast- and slow-multiplying bacterial
states. It is hence not possible to assign a specific number
of CFU to either the fast- or the slow-multiplying bacterial
state. Instead the model was allowed to estimate the
number of bacteria that belongs to the fast-multiplying and
the slow-multiplying bacterial state. The numbers in the
fast- and the slow- multiplying states, as a sum, were part
of the model prediction of the CFU data. A similar
approach of performing multiple states predictions based
on one observation has previously been utilized to describe
the life cycle of Plasmodium falciparum [8] and Strepto-
cocus pyogenes [20].
Rifampicin is effective against both replicating and non-
replicating bacteria because it targets essential and central
DNA machinery [21]. It is thought to inhibit the bacterial
DNA-dependent RNA polymerase [22]. In the final MTP
Fig. 2 Visual predictive check of the final Multistate Tuberculosis
Pharmacometric model applied to colony forming unit (CFU) data
from an acute tuberculosis mouse model. In the left-side figures, no
drug treatment (natural growth) was given and, in the right-side
figures, rifampicin 30 mgkg-1day-1 (the only dose level with
longitudinal observations) was given. The upper and lower figures are
from data above and below the lower limit of quantification (LLOQ).
In the upper figures, the solid black line is the median of the
observations. The horizontal solid grey line indicates the LLOQ of the
CFU data. Open circles represent the observations. The grey shaded
areas represent the 95% confidence intervals for the median of the
data simulated by the final model. In the lower plots, the black solid
line is the median of the data below the LLOQ. The grey shaded area
is the 95% confidence interval for the median of the data below the
LLOQ. There were no data below the LLOQ for the natural growth
experiments
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model, which incorporates fast-, slow- and non-multiplying
bacterial states, rifampicin significantly inhibited the
growth of fast-multiplying bacteria and stimulated the
death of fast- and slow-multiplying bacteria. Two separate
exposure–response relationships were identified for the
rifampicin effect on the stimulation of the death of fast-
multiplying and slow-multiplying bacterial states described
as non-linear and linear relationships, respectively. The
final model did not include a rifampicin effect on non-
multiplying bacteria as it was not statistically significant.
This was possibly due to that the non-growing subpopu-
lation was a minority segment of the total bacterial burden
in this acute tuberculosis mouse model. The MTP model
did not include any immune response element as it was
based on in vitro time-kill experiments lacking immune
response. However, an immune response may occur in an
in vivo system such as that represented by the mouse. The
MTP model could be extended to include immune response
components. However, it was not considered necessary for
this study, since the adaptive immune response under
similar experimental conditions [23] did not impair the
growth of M. tuberculosis during the assay period in
C57BL/6 mice. As such, there was no effect of the immune
system on the CFU versus time relationship in this study.
A limitation in this study was that PK information was
not collected from the mouse that provided the PD infor-
mation instead a PPP approach [13] was used. The popu-
lation PK model applied in this study was developed using
healthy animals [12], and we assumed that the PK would be
similar in the M. tuberculosis-infected animals used in the
PD experiments. The PK in infected animals, especially in
the acute infection setting, can be quite different compared
to healthy animals. In addition, the earlier developed
population PK model was built using data of only 3 days of
rifampicin administration, not fully capturing the auto-in-
duction process whereas in the current experiment animals,
rifampicin was dosed up to 8 days. In this study, a wide
dose range (1–98 mgkg-1) was studied. The applied
Fig. 3 Visual predictive check of the final Multistate Tuberculosis
Pharmacometric model applied to colony forming unit (CFU) data
using an acute tuberculosis mouse model from dose levels observed
only at Day 9 after infection. In the upper figure, log10 CFU/lungs
declined with increasing doses of rifampicin from 1 to 97.5 mgkg-1
day-1 measured at Day 9 after infection. The upper and lower
figures are from data above and below the lower limit of quantifi-
cation (LLOQ), respectively. In the upper figure, the solid black line
is the median of the observations. No median is shown for the dose of
26.4 mgkg-1 as this dose level only included two observations. The
horizontal solid grey line indicates the LLOQ of the CFU data. Open
circles represent the observations. The grey shaded areas represent
the 95% confidence intervals for the median of the data simulated
from the final model. In the lower figure, the black solid line is the
median of the data below the LLOQ. The grey shaded area is the 95%
confidence interval for the median of the data below the LLOQ
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population PK model was built on a dose range of rifam-
picin from 1 to 100 mgkg-1, which is covering the dose
range in this study where it was shown earlier that rifam-
picin PK is dose-dependent in this range. A PPP approach
ignores inter-animal variability in exposure and is therefore
less informative than the use of PK information from the
animal in which the PD response was obtained. However,
the inter-animal variability is likely to be low but potential
differences between healthy and diseased animals (co-
variate effect) are not known.
Conclusions
The MTP model described the changes in CFU over time
well in an acute tuberculosis mouse model and rifampicin
treatment effects on different bacterial states were char-
acterised. The pharmacometric modelling framework using
the MTP model can be used to perform investigations and
predictions of the efficacy of anti-tubercular drugs against
different bacterial states.
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